Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EPOPROSTENOL Cause Condition aggravated? 818 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 818 reports of Condition aggravated have been filed in association with EPOPROSTENOL (EPOPROSTENOL). This represents 6.1% of all adverse event reports for EPOPROSTENOL.

818
Reports of Condition aggravated with EPOPROSTENOL
6.1%
of all EPOPROSTENOL reports
289
Deaths
648
Hospitalizations

How Dangerous Is Condition aggravated From EPOPROSTENOL?

Of the 818 reports, 289 (35.3%) resulted in death, 648 (79.2%) required hospitalization, and 63 (7.7%) were considered life-threatening.

Is Condition aggravated Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EPOPROSTENOL. However, 818 reports have been filed with the FAERS database.

What Other Side Effects Does EPOPROSTENOL Cause?

Dyspnoea (2,744) Headache (2,425) Diarrhoea (2,310) Nausea (2,016) Pain in jaw (1,928) Death (1,362) Flushing (1,256) Fatigue (1,133) Hospitalisation (1,078) Vomiting (1,068)

What Other Drugs Cause Condition aggravated?

TOFACITINIB (16,925) INFLIXIMAB (16,616) DUPILUMAB (16,459) ETANERCEPT (15,897) METHOTREXATE (14,938) ADALIMUMAB (13,527) PREDNISONE (10,751) INFLIXIMAB-DYYB (10,275) HYDROXYCHLOROQUINE (8,848) RITUXIMAB (8,627)

Which EPOPROSTENOL Alternatives Have Lower Condition aggravated Risk?

EPOPROSTENOL vs EPTIFIBATIDE EPOPROSTENOL vs EPTINEZUMAB-JJMR EPOPROSTENOL vs EPTINEZUMAB\EPTINEZUMAB-JJMR EPOPROSTENOL vs EQUINE BOTULINUM NEUROTOXIN A/B/C/D/E/F/G IMMUNE FAB2 EPOPROSTENOL vs EQUINE THYMOCYTE IMMUNE GLOBULIN

Related Pages

EPOPROSTENOL Full Profile All Condition aggravated Reports All Drugs Causing Condition aggravated EPOPROSTENOL Demographics